Annals of Oncology Advance Access originally published online on January 15, 2009
Annals of Oncology 2009 20(4):621-627; doi:10.1093/annonc/mdn682
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
breast cancer |
Survival among women with triple receptor-negative breast cancer and brain metastases
1 Department of Breast Medical Oncology
2 Department of Quantitative Sciences
3 Department of Pathology
4 Department of Radiation Oncology
5 Department of Radiology, The University of Texas M. D. Anderson Cancer Center, Houston, USA
6 Department of Medical Oncology, Dubai Hospital, United Arab Emirates
* Correspondence to: Dr S. Dawood, Department of Medical Oncology, Dubai Hospital, PO Box 8179, Dubai, United Arab Emirates. Tel: +971-50-7289797; Fax: +97143527776; E-mail: shaheenah{at}post.harvard.edu
Background: The purpose of this study was to determine the incidence of and survival following brain metastases among women with triple receptor-negative breast cancer.
Patients and methods: In all, 679 patients with nonmetastatic triple receptor-negative breast cancer diagnosed from 1980 to 2006 were identified. Cumulative incidence of brain metastases was computed. Cox proportional hazards models were fitted to explore factors that predict for development of brain metastases. Survival was computed using the Kaplan–Meier product limit method.
Results: Median follow-up was 26.9 months. In all, 42 (6.2%) patients developed brain metastases with a cumulative incidence at 2 and 5 years of 5.6% [95% confidence interval (CI) 3.8% to 7.9%] and 9.6% (95% CI 6.8% to 13%), respectively. A total of 24 (3.5%) patients developed brain metastases as the first site of recurrence with cumulative incidence at 2 and 5 years of 2.0% (95% CI 2.6% to 6.0%) and 4.9% (95% CI 3.2% to 7.0%), respectively. In the multivariable model, no specific factor was observed to be significantly associated with time to brain metastases. Median survival for all patients who developed brain metastases and those who developed brain metastases as the first site of recurrence was 2.9 months (95% CI 2.0–7.6 months) and 5.8 months (95% CI 1.7–11.0 months), respectively.
Conclusion: In this single-institutional study, patients with nonmetastatic triple receptor-negative breast tumors have a high early incidence of brain metastases associated with poor survival and maybe an ideal cohort to target brain metastases preventive strategies.
Key words: brain metastases, breast cancer, triple negative
Received for publication September 17, 2008. Accepted for publication September 24, 2008.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  O. Gluz, C. Liedtke, N. Gottschalk, L. Pusztai, U. Nitz, and N. Harbeck Triple-negative breast cancer--current status and future directions Ann. Onc., December 1, 2009; 20(12): 1913 - 1927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Brain Metastases in Triple-Negative Breast Cancer Journal Watch Oncology and Hematology, May 26, 2009; 2009(526): 2 - 2. [Full Text]
|
|
|
|
|
|
B. C. Pestalozzi Brain metastases and subtypes of breast cancer Ann. Onc., May 1, 2009; 20(5): 803 - 805. [Full Text] [PDF]
|
|